Premium
Plasticity of bone marrow‐derived dendritic cells (DC) as immunotherapy vaccines
Author(s) -
Jungsuwadee Paiboon
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.715.3
Subject(s) - ovalbumin , immune system , cd40 , dendritic cell , lipopolysaccharide , microbiology and biotechnology , antigen , immunology , antigen presenting cell , chemistry , t cell , antigen presentation , follicular dendritic cells , bone marrow , biology , cytotoxic t cell , in vitro , biochemistry
Dependingon microenvironment, dendritic cells (DCs) may activate and differentiate naïveCD4+ T cells into Th1 or Th2 phenotypes when bacterial lipopolysaccharide (LPS)or allergen is present, respectively. The combination of antigens with Toll‐like receptor (TLR) ligands such as LPS enhances DCs activities compared to antigen alone. However, in such combinations, it is not clear to which direction CD4+ T cells will be polarized into. Here, we investigated there sponse of CD4+ T cell to DCs loaded with ovalbumin (OVA) or endotoxin‐depletedovalbumin (OVA ED ) vs. LPS‐stimulated DCs. Up on exposure to antigens, DCs became matured as indicated by up‐regulation of MHC and costimulatory molecules and increased secretion of IL‐10 and IL‐12. Interestingly, the levels of CD40 expression, and IL‐10 and IL‐12 productions appeared to be correlated with LPS levels. LPS‐stimulated DCs induced naïveCD4+ T cells to produce more IFNγ while OVA ED ‐stimulated DCs induced T cells to produce more IL‐4. Addition of LPS into OVA ED ‐stimulated DCs during T cell activation compromised the production of IL‐4. These results suggest that DC maturationcan be polarized into type 1 (LPS‐stimulated) or type 2 (Allergen‐stimulated)DCs influenced by the nature of antigens. Type 1 DCs promote Th1 while Type 2DCs promote Th2 immune responses. This plasticity of DCs provide a flexibility for applications in the development of DC‐based vaccines.